---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-162652"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:05:30.965861+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024

## Summary
- Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.
- Ogden continues as Principal Accounting and Financial Officer, roles held since September 2022.
- Granted option to purchase 75,000 shares and RSU award for 17,500 shares under 2015 Equity Incentive Plan.
- No family relationships or arrangements with other parties in connection with his appointment.

## SEC filing metadata
- accession: 0001193125-24-162652
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/0001193125-24-162652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/d831468d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-162652
- JSON: https://secwatch.observer/filing/0001193125-24-162652.json
- Plain text: https://secwatch.observer/filing/0001193125-24-162652.txt

## Key facts
- Executive change
  Chris Ogden was appointed as Chief Financial Officer at CytomX Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/0001193125-24-162652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.